Rezdiffra Efficacy Shown Consistent Across Genetic Variants
A secondary analysis found that Rezdiffra performed consistently regardless of common genetic risk variants in MASH patients.
Updated on Oct. 6, 2026 in Diabetes
Live Poll
Do you trust that new medical treatments are sufficiently tested for patients with different genetic backgrounds?
Madrigal Pharmaceuticals has published a secondary analysis of its Phase 3 MAESTRO-NASH trial in the Journal of Hepatology. The study demonstrates that the drug Rezdiffra maintains consistent efficacy across multiple genetic risk variants associated with MASH.
Why it matters
Understanding if common risk alleles influence drug response is essential for clinicians evaluating treatment pathways for MASH patients. The findings suggest that patients can expect similar outcomes regardless of their underlying genetic profile.
The analysis of 738 patients revealed that Rezdiffra efficacy remains consistent across PNPLA3, HSD17B13, TM6SF2, MTARC1, and MBOAT7 variants. Researchers compared outcomes against placebo, noting 38.4% MASH resolution in the low-risk PNPLA3 genotype group.
The players
Madrigal Pharmaceuticals
Based in Conshohocken, Pennsylvania, this clinical-stage biopharmaceutical company focuses on developing novel therapeutics for NASH.
Journal of Hepatology
This is a peer-reviewed medical journal that publishes original research and reviews concerning liver diseases and hepatology.
The details
The analysis evaluated patient biopsy data collected at baseline and again at Week 52. Researchers specifically looked for differences in treatment response between the Rezdiffra and placebo groups across identified genetic risk subgroups.
Timeline
May 2026: Madrigal added MGL-0795 to its drug pipeline.
Week 52: Patients completed final liver biopsies for the study.
October 6, 2026: Madrigal announced the publication of the analysis.
The Big Picture
This study validates the therapeutic reach of the MAESTRO-NASH trial across diverse patient populations. It provides necessary clinical assurance that a standard drug regimen remains effective for patients regardless of their specific genetic predispositions.
Patients with MASH can benefit from the knowledge that their specific genetic markers likely will not change the efficacy of this prescribed treatment. This consistency simplifies the decision-making process for both patients and healthcare providers when considering Rezdiffra.
The takeaway
The study suggests that genetic testing may not be a prerequisite for predicting success with this MASH medication. Clinicians can utilize these findings to offer a standardized treatment approach to a broader range of patients.
What happens next
Madrigal Pharmaceuticals plans to consult with the FDA regarding the design of a Phase 2 combination trial for Rezdiffra.
Further reading
For additional context on metabolic research, see the Diabetes section.
Live Poll
Do you trust that new medical treatments are sufficiently tested for patients with different genetic backgrounds?
